Novocure Is Maintained at In-Line by Evercore ISI Group
NovoCure Analyst Ratings
Evercore Maintains Novocure(NVCR.US) With Hold Rating, Cuts Target Price to $18
Wells Fargo Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $40
Wells Fargo Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $40
Wells Fargo Remains a Buy on NovoCure (NVCR)
Novocure Price Target Raised to $24.00/Share From $22.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Neutral on NovoCure, Raises Price Target to $24
NovoCure Analyst Ratings
H.C. Wainwright Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $24
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $28
NovoCure Analyst Ratings
Evercore ISI Group Maintains In-Line on NovoCure, Raises Price Target to $20
NovoCure Analyst Ratings
Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Arrowhead Pharmaceuticals (ARWR) and NovoCure (NVCR)
NovoCure Analyst Ratings
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)
Piper Sandler: Reiterates the NovoCure (NVCR.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $25.00 to $28.00.
NovoCure Analyst Ratings